ArticleAnnals of surgical oncology2026

Clinical Outcomes of First-Line Immune Checkpoint Inhibitor-Based Therapy for Postoperative Recurrence After Adjuvant Nivolumab in Esophageal Cancer.

Takahito Sugase et al.PubMed ↗Publisher ↗

No numbers read from the abstract.